Avaí Bio, JV Partner Austrianova Announce First Joint Steering Committee Meeting For Partnership With Ospedale San Raffaele Over Discussion On Initial Research Program To Mull Encapsulated Beta-Cell Replacement Approach For Insulin-Dependent Diabetes
Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company") and its joint venture partner Austrianova, today announced the first joint steering committee meeting for their collaboration with Ospedale San
Share
Why It Matters
Avaí Bio started planning with partners on a diabetes treatment project. This shows the company is moving forward on its science work.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.